Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma
Phase of Trial: Phase II
Latest Information Update: 19 Mar 2018
At a glance
- Drugs Deuteporfin (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- 15 Mar 2018 Planned End Date changed from 1 Jun 2018 to 1 May 2019.
- 15 Mar 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Mar 2019.
- 10 Jun 2017 Biomarkers information updated